Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)

CAPS Rating: 3 out of 5

EGRX News and Commentary

Caps

How do you think EGRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

53 Outperform
3 Underperform
 

All-Star Players

16 Outperform
0 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top EGRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

EPS100Momentum (73.67)
Submitted March 18, 2015

The next JAZZ in the making.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

EGRX VS S&P 500 (SPY)

Fools bullish on EGRX are also bullish on:

Fools bearish on EGRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EGRX.

Recs

0
Member Avatar healthcarevalue (93.07) Submitted: 8/22/2017 11:47:27 PM : Outperform Start Price: $53.90 EGRX Score: -0.75

EGRX, Eagle Pharmaceuticals, is an attractive healthcare sector stock that is undervalued at this point in time with a price earnings ratio of about nine for the last twelve trailing months, a debt/equity ratio of negligible to nothing to speak of, and a return on invested capital of over seventy for the last twelve trailing months. The stock is currently towards the lower end of its 52 week range. The company's medical products related to both oncology and critical care are high need areas for its particular set of drugs. The company's specialty pharamceutical niche sets it apart as a differentiated area for potential growth and or an attractive candidate for potential acquisition by other pharmaceutical companies wishing to expand their research and development portfolios. Its market cap of under one billion, combined with its low debt and low price/earnings ratio, make it a potentially attractive acquisition candidate.

Recs

0
Member Avatar bkinvest (62.89) Submitted: 8/4/2017 10:45:31 AM : Outperform Start Price: $46.92 EGRX Score: +16.22

Great bio company with plenty of promising drug candidates in the pipeline. Took a huge dip with FDA rejection of heat stroke candidate and asked for another Clinical Study. If they decide not to proceed with another study; it is not the end of the world. Great opportunity for the patient investor

Recs

0
Member Avatar cibient (< 20) Submitted: 4/27/2016 3:31:57 PM : Outperform Start Price: $40.16 EGRX Score: +17.83

Bret Jensen - seekingalpha high conviction article on 4/22/16.

Leaderboard

Find the members with the highest scoring picks in EGRX.

Score Leader

karakartal

karakartal (< 20) Score: +346.60

The Score Leader is the player with the highest score across all their picks in EGRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Turdtwistr 61.96 2/5/2015 Outperform 5Y $19.01 +199.58% +26.91% +172.67 0 Comment
zackstracker1 48.98 2/29/2016 Underperform NS $68.08 -16.35% +33.25% +49.60 0 Comment
jmdor2222 79.42 11/2/2016 Underperform 5Y $69.64 -18.22% +23.65% +41.87 0 Comment
Bearbob63 28.89 2/19/2015 Outperform 5Y $34.67 +64.26% +24.15% +40.11 0 Comment
Ander89 81.10 3/3/2015 Outperform 5Y $37.76 +50.82% +22.94% +27.88 0 Comment
NoDoughBro 70.87 3/3/2015 Outperform 5Y $37.76 +50.82% +22.94% +27.88 0 Comment
GreenAB 97.02 3/5/2015 Outperform NS $39.40 +44.54% +23.41% +21.13 0 Comment
cibient < 20 4/27/2016 Outperform 5Y $40.16 +41.81% +23.98% +17.83 1 Comment
bkinvest 62.89 8/4/2017 Outperform 5Y $46.92 +21.38% +5.16% +16.22 1 Comment
germanjuggler 70.22 6/10/2016 Underperform 5Y $52.81 +7.85% +23.78% +15.93 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackmizuho < 20 11/3/2016 Outperform NS $70.37 -19.07% +23.81% -42.88 0 Comment
TrackCreditSuiss 90.68 3/31/2015 Outperform NS $40.93 +39.14% +25.44% +13.70 0 Comment

Featured Broker Partners